Big Early Effects in Immunosuppressive Therapy Predict Better Outcomes
Greater reductions in the levels of antibodies against the acetylcholine receptor (AChR) within the first three months after immunosuppressive…
Articles by Marta Figueiredo, PhD
Disease Crisis Linked to Distinct Pro-inflammatory Immune Changes
Myasthenia gravis (MG) crisis, the disease’s most severe state, is associated with pronounced pro-inflammatory cellular and molecular changes, a…
Eurordis Survey: Healthcare Experience Worse for Rare Disease Patients
People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of…
International Experts Update, Expand MG Management Guidelines
A panel of 16 international experts has updated and expanded the recommendations for best management of myasthenia gravis (MG),…
Dysarthria in MG Linked to Changes in Breathing, Other Motor Bases of Speech
In people with myasthenia gravis (MG), slow or slurred speech, called dysarthria, is associated with changes in three motor…
Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe
The first wave of COVID-19Â in Europe severely disrupted access to care and raised stress and anxiety in people with…
Age, Type of Surgery Linked to Thymoma Relapse Risk in MG Patients
Among myasthenia gravis (MG) patients whose thymomas — tumors of the thymus — are surgically removed, those who are…
Early Anticholinesterase Use May Benefit MG Patients With Thymus Tumor
Among people with myasthenia gravis (MG) and thymoma — a tumor of the thymus — being male and having…
Efgartigimod Ably Treats AChR-positive Patients in Phase 3 Trial, Data Show
Argenx’s lead candidate efgartigimod (ARGX-113) safely and effectively eases symptoms in people with generalized myasthenia gravis (gMG) who have…
Thymectomy Seen to Aid Remission in Ocular MG Patients Younger Than 40
People who develop ocular myasthenia gravis (OMG) before age 40 are more likely to go into remission after surgery…